Canada markets open in 2 hours 55 minutes
  • S&P/TSX

    21,216.15
    +3.75 (+0.02%)
     
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • DOW

    35,677.02
    +73.92 (+0.21%)
     
  • CAD/USD

    0.8093
    +0.0002 (+0.02%)
     
  • CRUDE OIL

    84.53
    +0.77 (+0.92%)
     
  • BTC-CAD

    77,418.65
    +1,484.27 (+1.95%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • GOLD FUTURES

    1,800.10
    +3.80 (+0.21%)
     
  • RUSSELL 2000

    2,291.27
    -4.91 (-0.21%)
     
  • 10-Yr Bond

    1.6550
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,378.75
    +37.75 (+0.25%)
     
  • VOLATILITY

    15.91
    +0.90 (+6.00%)
     
  • FTSE

    7,244.82
    +40.27 (+0.56%)
     
  • NIKKEI 225

    28,600.41
    -204.44 (-0.71%)
     
  • CAD/EUR

    0.6961
    +0.0019 (+0.27%)
     

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - September 23, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021.

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19811&wire=5

Allegations against SAVA include that the Company made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.

If you suffered a loss in Cassava you have until October 26, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97488

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting